Original Research, Human Studies, Pharmacology/Drug Development, Itch, Psychology

Psoriatic arthritis (PsA) is a heterogeneous disease that impacts many aspects of social and mental life, including quality of life. Risankizumab, an antagonist specific for interleukin-23 (IL-23), is currently under investigation for the treatment of adults with active PsA. This study evaluated the impact of risankizumab versus placebo on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) among patients with active PsA and inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs (csDMARD-IR) in the KEEPsAKE 1 trial.